1. Home
  2. AARD vs LFVN Comparison

AARD vs LFVN Comparison

Compare AARD & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AARD
  • LFVN
  • Stock Information
  • Founded
  • AARD 2017
  • LFVN N/A
  • Country
  • AARD United States
  • LFVN United States
  • Employees
  • AARD N/A
  • LFVN N/A
  • Industry
  • AARD Biotechnology: Pharmaceutical Preparations
  • LFVN Biotechnology: Pharmaceutical Preparations
  • Sector
  • AARD Health Care
  • LFVN Health Care
  • Exchange
  • AARD Nasdaq
  • LFVN Nasdaq
  • Market Cap
  • AARD 154.9M
  • LFVN 165.9M
  • IPO Year
  • AARD 2025
  • LFVN N/A
  • Fundamental
  • Price
  • AARD $13.77
  • LFVN $13.39
  • Analyst Decision
  • AARD Strong Buy
  • LFVN Strong Buy
  • Analyst Count
  • AARD 5
  • LFVN 2
  • Target Price
  • AARD $33.00
  • LFVN $30.50
  • AVG Volume (30 Days)
  • AARD 77.3K
  • LFVN 163.3K
  • Earning Date
  • AARD 08-14-2025
  • LFVN 05-06-2025
  • Dividend Yield
  • AARD N/A
  • LFVN 1.21%
  • EPS Growth
  • AARD N/A
  • LFVN 152.87
  • EPS
  • AARD N/A
  • LFVN 0.70
  • Revenue
  • AARD N/A
  • LFVN $222,347,000.00
  • Revenue This Year
  • AARD N/A
  • LFVN $17.36
  • Revenue Next Year
  • AARD N/A
  • LFVN $9.60
  • P/E Ratio
  • AARD N/A
  • LFVN $18.81
  • Revenue Growth
  • AARD N/A
  • LFVN 8.22
  • 52 Week Low
  • AARD $4.88
  • LFVN $5.22
  • 52 Week High
  • AARD $19.58
  • LFVN $27.38
  • Technical
  • Relative Strength Index (RSI)
  • AARD N/A
  • LFVN 52.38
  • Support Level
  • AARD N/A
  • LFVN $11.50
  • Resistance Level
  • AARD N/A
  • LFVN $12.90
  • Average True Range (ATR)
  • AARD 0.00
  • LFVN 0.45
  • MACD
  • AARD 0.00
  • LFVN 0.02
  • Stochastic Oscillator
  • AARD 0.00
  • LFVN 95.07

About AARD Aardvark Therapeutics Inc. Common Stock

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

About LFVN Lifevantage Corporation (Delaware)

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

Share on Social Networks: